Myra Vision website screenshot

Myra Vision

Myra Vision, Inc. is a clinical-stage ophthalmic medical device company headquartered in Campbell, California, and a privately held portfolio company of the Shifamed LLC medical device incubator. It develops the Calibreye Titratable Glaucoma Therapy (TGT) Surgical System, an aqueous shunt for patients with moderate to severe glaucoma whose valve-controlled outflow channels use shape-memory nitinol and can be reversibly opened or closed in-office with a transcorneal laser, letting a clinician titrate intraocular pressure after implantation rather than committing to a fixed flow at the time of surgery. The company completed first-in-human use of the Calibreye System in 2023, received FDA conditional approval of its Investigational Device Exemption in August 2025, and enrolled the first patient in its US ADAPT clinical study in January 2026. As a medical device manufacturer its product is a physical implant and a surgical procedure, not software: Myra Vision publishes no public developer API, SDK, developer portal, or machine-readable API specification, and this profile captures its corporate identity and public web properties in the API Evangelist network.

Myra Vision is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Healthcare, Ophthalmology, and Glaucoma.

🌐 Visit website 📡 Source on GitHub
7.6/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyMedical DevicesHealthcareOphthalmologyGlaucomaLife SciencesMedical TechnologyClinical Stage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 7.6/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Commercial Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 3.9 / 9
Regulatory Posture 1.9 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/myra-vision: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Myra Vision Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 2

The organization behind the API

Website
Website
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: myra-vision
name: Myra Vision
description: 'Myra Vision, Inc. is a clinical-stage ophthalmic medical device company headquartered in Campbell, California,
  and a privately held portfolio company of the Shifamed LLC medical device incubator. It develops the Calibreye Titratable
  Glaucoma Therapy (TGT) Surgical System, an aqueous shunt for patients with moderate to severe glaucoma whose valve-controlled
  outflow channels use shape-memory nitinol and can be reversibly opened or closed in-office with a transcorneal laser, letting
  a clinician titrate intraocular pressure after implantation rather than committing to a fixed flow at the time of surgery.
  The company completed first-in-human use of the Calibreye System in 2023, received FDA conditional approval of its Investigational
  Device Exemption in August 2025, and enrolled the first patient in its US ADAPT clinical study in January 2026. As a medical
  device manufacturer its product is a physical implant and a surgical procedure, not software: Myra Vision publishes no public
  developer API, SDK, developer portal, or machine-readable API specification, and this profile captures its corporate identity
  and public web properties in the API Evangelist network.'
url: https://raw.githubusercontent.com/api-evangelist/myra-vision/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Medical Devices
- Healthcare
- Ophthalmology
- Glaucoma
- Life Sciences
- Medical Technology
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/myra-vision-domain-security.yml
- type: Website
  url: https://www.myravision.com/
- type: PrivacyPolicy
  url: https://www.myravision.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/myra-vision
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Myra Vision is a 25-person clinical-stage medical device maker whose product is the Calibreye titratable glaucoma
    shunt — a nitinol implant adjusted in-office by laser, not software; its entire web presence is a five-page WordPress
    marketing site (home, sign-up, privacy policy, titratable-outflow, 404) with no developer, docs, or api subdomain resolving
    in DNS, no GitHub organization, and no package on npm/PyPI, and the origin additionally answers every path with a SiteGround
    captcha challenge (HTTP 202) so live /.well-known and /openapi.json probes were confirmed against archived crawls instead.
  evidence:
  - url: https://www.myravision.com/
    status: 202
  - url: https://www.myravision.com/openapi.json
    status: 202
  - url: https://web.archive.org/web/20250305100237id_/https://www.myravision.com/page-sitemap.xml
    status: 200
  - url: https://web.archive.org/web/20250306013206/https://www.myravision.com/.well-known/security.txt
    status: 404
  - url: https://api.github.com/orgs/myravision
    status: 404
  checked: '2026-08-04'